0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About HTG Molecular Diagnostics
Its shares trade under the ticker HTGMQ. It has been listed since 6 May 2015. In the fiscal year to 31 December 2022, it reported revenue of $6.4m and a net loss of $21.6m. At that date it held total assets of $17.8m and shareholders' equity of $5.4m.
HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. The company is headquartered in Tucson, Arizona. The company went IPO on 2015-05-06. The firm is focused on advancing precision medicine and drug discovery through its transcriptome-wide profiling and advanced drug discovery platform technologies. The firm is engaged in the sales of its HTG EdgeSeq system and integrated next-generation sequencing-based (NGS-based) HTG EdgeSeq research use only (RUO) assays and from sample processing services. Its HTG EdgeSeq profiling technology measures ribonucleic acid (RNA) using deoxyribonucleic acid (DNA) nuclease protection probes (DNA protection probes). Its profiling product and service solutions enable targeted RNA profiling using a small amount of biological sample, in liquid or solid forms. Its menu of HTG EdgeSeq assays includes the HTG Transcriptome Panel (HTP), which is designed to measure approximately 20,000 mRNA targets using its HTG EdgeSeq technology, is automated on its HTG EdgeSeq system.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Technology
- Listed since
- 6 May 2015
- Employees
- 53
- Website
- htgmolecular.com ↗
Leadership
Pay as last reported
- Dr. Ann HanhamIndependent Chair of Board of Directors, since 2016$80,048
- Mr. John LubniewskiPresident, Chief Executive Officer, Director, since 2011$913,891
- Mr. Shaun McmeansSenior Vice President, Chief Financial Officer, Treasurer, Secretary$580,316
- Dr. Stephen BaratSenior Vice President of Therapeutics , Executive Officer
- Dr. Thomas DubenskyIndependent Director$11,004
- Ms. Michelle GriffinIndependent Director$54,753
- Mr. Donnie HardisonIndependent Director$49,524
- Mr. Christopher KiritsyIndependent Director$53,832
- Mr. Lee McCrackenIndependent Director$49,407
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- HTG EdgeSeq system enables targeted RNA profiling with small biological samples.
- HTG Transcriptome Panel measures approximately 20,000 mRNA targets for precision medicine.
- HTG EdgeSeq technology uses DNA protection probes for RNA measurement.
Weaknesses
- 53 employees limit scalability for global expansion.
- Tucson headquarters restricts access to major biotech hubs.
- IPO in 2015 limits recent capital for R&D.
Opportunities
- Precision medicine market growth offers new assay development opportunities.
- HTG EdgeSeq system adoption in research institutions increases demand.
- RNA profiling technology can expand into drug discovery applications.
Threats
- Competition from larger biotech firms in molecular diagnostics.
- Regulatory changes in healthcare could impact assay approvals.
- Global economic downturn may reduce research funding.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.